Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping VASOSTRICT ®, vasopressin injection, USP, in ready-to-use 100 mL pre-mix bottles.

Endo's Par sued Eagle in 2018 after it requested U.S. Food and Drug Administration approval of a generic version of Vasostrict. Chief U.S. District Judge Colm Connolly ruled last year that Eagle ...

Endo International plc’s ENDP shares ... has issued a new patent (U.S. Patent No. 9,375,478) for a drug, Vasostrict (vasopressin injection, USP) 20 units/mL, belonging to one of its operating ...

Vasostrict, indicated to increase blood ... QuVa was founded in 2015 by former executives at Endo's subsidiary Par Sterile Products Llc.

for Par Sterile Products, LLC's VASOSTRICT product. Because the court found non-infringement of Endo's patents by Eagle's proposed product, it did not rule on the patents' validity. "We are ...

Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo ...

Fresenius Kabi USA LLC on Tuesday lost an antitrust lawsuit alleging a subsidiary of rival Endo International PLC ... versions of its blood pressure drug Vasostrict from hitting the market.